Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment

Gu, Yanyun; Wang, Xiaokai; Li, Junhua; Zhang, Yifei; Zhong, Huanzi; Liu, Ruixin; Zhang, Dongya; Feng, Qiang; Xie, Xiaoyan; Hong, Jie; Ren, Huahui; Liu, Wei; Ma, Jing; Su, Qing; Zhang, Hongmei; Yang, Jialin; Wang, Xiaoling; Zhao, Xinjie; Gu, Weiqiong; Bi, Yufang; Peng, Yongde; Xu, Xiaojiang; Xia, Huihua; Li, Fang; Xu, Xun; Yang, Huanming; Xu, Guowang; Madsen, Lise; Kristiansen, Karsten; Ning, Guang; Wang, Weiqing

Published in:
Nature Communications

DOI:
10.1038/s41467-017-01682-2

Publication date:
2017

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Antidiabetic medication may modulate the gut microbiota and thereby alter plasma and faecal bile acid (BA) composition, which may improve metabolic health. Here we show that treatment with Acarbose, but not Glipizide, increases the ratio between primary BAs and secondary BAs and plasma levels of unconjugated BAs in treatment-naive type 2 diabetes (T2D) patients, which may beneficially affect metabolism. Acarbose increases the relative abundances of Lactobacillus and Bifidobacterium in the gut microbiota and depletes Bacteroides, thereby changing the relative abundance of microbial genes involved in BA metabolism. Treatment outcomes of Acarbose are dependent on gut microbiota compositions prior to treatment. Compared to patients with a gut microbiota dominated by Prevotella, those with a high abundance of Bacteroides exhibit more changes in plasma BAs and greater improvement in metabolic parameters after Acarbose treatment. Our work highlights the potential for stratification of T2D patients based on their gut microbiota prior to treatment.
The importance of the intestinal microbiota in host health and pathogenesis of several non-communicable diseases such as cancer, obesity, and type 2 diabetes (T2D), and even mental disorders is now recognised\(^2\).\(^5\) Cross-sectional case-control studies have revealed microbial dysbiosis in T2D patients\(^3\)\(^\sim\)\(^6\), possibly contributing to disease development. Although solid proof of a causal link between gut microbial dysbiosis and T2D is still missing, it has been reported that therapeutic strategies such as bariatric surgery\(^7\)\(^\sim\)\(^9\) and Metformin treatment\(^1\)\(^\sim\)\(^3\) may confer metabolic benefits including improved glycaemic control through alteration of the gut microbiota. Furthermore, recent studies have demonstrated that single bacterial species associated with insulin resistance and obesity upon transfer to normal specific pathogen-free (SPF) mice confer the same phenotype to the recipient mice\(^10\)\(^\sim\)\(^11\).

Host-gut microbiota interaction is central in bile acid (BA) metabolism and signalling, and it is essential for the maintenance of metabolic health\(^12\). Additionally, compared to healthy individuals, alterations in the levels and compositions of plasma BAs have been observed in patients with diabetes or obesity\(^13\)\(^\sim\)\(^15\), further highlighting a possible involvement of BA metabolism in the pathogenesis of metabolic diseases. Finally, an animal study further highlighting a possible involvement of BA metabolism in the same phenotype to the recipient mice\(^10\)\(^\sim\)\(^11\).

Acarbose, a pseudo-tetrasaccharide produced by *Actinoplanes* species and an alpha-glycosidase inhibitor, is recommended in China and other Asian countries as an alternative to Metformin for first line treatment of T2D17\(^\sim\)\(^19\). Unlike classic oral anti-diabetic drugs (OADs) such as thiazolidinediones or sulfonylureas (SUs)\(^20\) with well-characterised molecular targets affecting insulin resistance or secretion, Acarbose exerts its hypoglycaemic effects by inhibiting the hydrolysis of complex carbohydrates on the brush border of the upper intestinal epithelium thereby reducing glucose absorption in this part of the intestine. This further leads to an increased concentration of complex carbohydrates in the lower part of the intestine\(^21\), potentially altering microbial fermentation in the distal gut.

To elucidate how OADs may affect the gut microbiota, and discriminate such changes from disease-dependent alterations, intervention studies are needed on treatment-naïve T2D patients admitted to antidiabetic treatment. In a multicentre, randomised and positively controlled clinical trial, where treatment-naïve T2D patients were assigned to treatment with one of two drugs commonly used in China, Acarbose or the sulfonylurea Glipizide, to achieve targeted glycaemic control, we compared the effects of the two drugs on metabolic parameters, including plasma BAs, and the intestinal microbiota. We identify drug-dependent alterations in the microbiome and plasma BAs that correlate with clinical measurements and outcomes, including body mass index (BMI), blood glucose, glycated haemoglobin (HbA1c), lipid profiles, insulin secretion and resistance status. Of interest, treatment-naïve T2D patients can be stratified into two groups based on their individual baseline microbiomes. Patients harbouiring a gut microbiota with a higher baseline abundance of *Bacteroides* have lower levels of secondary BAs and exhibit more beneficial therapeutic responses to Acarbose treatment, including reduced BMI, and improved insulin resistance status and lipid profile, suggesting that baseline metagenome signatures may be used to stratify T2D patients prior to treatment.

### Results

#### Baseline characteristics of patients and clinical outcomes.

To characterise the clinical effects of Acarbose and Glipizide, we

### Table 1 Clinical parameters in the pre-treatment and post-treatment samples in the two treatment arms

<table>
<thead>
<tr>
<th></th>
<th>Pre-treatment</th>
<th>Post-treatment</th>
<th>P value Pre vs. Post</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>53 ± 7</td>
<td>54 ± 7</td>
<td>0.497</td>
</tr>
<tr>
<td>Gender (male/total)</td>
<td>34/51</td>
<td>24/43</td>
<td>0.387</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>74.7 ± 10.3</td>
<td>71.5 ± 10.7</td>
<td>0.067</td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
<td>26.3 ± 3.2</td>
<td>26.0 ± 3.4</td>
<td>0.265</td>
</tr>
<tr>
<td>WC (cm)</td>
<td>91.5 ± 8.5</td>
<td>90.7 ± 8.4</td>
<td>0.527</td>
</tr>
<tr>
<td>WHR</td>
<td>0.92 ± 0.06</td>
<td>0.92 ± 0.05</td>
<td>0.485</td>
</tr>
<tr>
<td><strong>Glycaemic characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>7.5 ± 0.8</td>
<td>7.7 ± 0.9</td>
<td>0.541</td>
</tr>
<tr>
<td>FPG (mmol/L)</td>
<td>7.6 ± 1.4</td>
<td>7.9 ± 1.4</td>
<td>0.291</td>
</tr>
<tr>
<td>PPG (mmol/L)</td>
<td>14.3 ± 2.7</td>
<td>15.0 ± 2.8</td>
<td>0.164</td>
</tr>
<tr>
<td>AUC blood glucose (mmol/L)</td>
<td>224 ± 363</td>
<td>238 ± 351</td>
<td>0.077</td>
</tr>
<tr>
<td>AUC Insulin (pmol/L/min)</td>
<td>5981 ± 3340</td>
<td>5460 ± 2507</td>
<td>0.697</td>
</tr>
<tr>
<td>AUC C Peptide (ng/ml/min)</td>
<td>528 ± 210</td>
<td>501 ± 154</td>
<td>0.978</td>
</tr>
<tr>
<td>HOMA-IR (μIU * mmol)</td>
<td>3.7 ± 2.3</td>
<td>3.6 ± 2.1</td>
<td>0.868</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>127 ± 16</td>
<td>131 ± 18</td>
<td>0.431</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>82 ± 8</td>
<td>81 ± 10</td>
<td>0.675</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>2.5 ± 2.1</td>
<td>2.1 ± 1.2</td>
<td>0.459</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>5.1 ± 1.2</td>
<td>4.9 ± 1.0</td>
<td>0.696</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/L)</td>
<td>1.2 ± 0.4</td>
<td>1.0 ± 0.3</td>
<td>0.500</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L)</td>
<td>3.1 ± 0.8</td>
<td>3.0 ± 1.0</td>
<td>0.492</td>
</tr>
<tr>
<td>FRI</td>
<td>334 ± 554</td>
<td>237 ± 341</td>
<td>0.352</td>
</tr>
</tbody>
</table>

\(^1\)WC, waist circumference; WHR, waist:hip circumference ratio; HbA1c, glycated haemoglobin; FPG, fasting plasma glucose; PPG, postprandial plasma glucose; AUC, area under the curve; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FLI, fatty liver index. FLI = (0.005 × loge (TG) + 0.139 × BMI + 0.718 × loge [γGT] + 0.053 × WC − 15.745)/[(1 + e\(^0.953\) × loge [TG] + 0.139 × BMI + 0.718 × loge [γGT] + 0.053 × WC − 15.745)] + 100. γGT, gamma-glutamyltransferase

Data are presented as mean ± SD
recruited patients from five centres in Shanghai, China. A total of 171 treatment-naive T2D patients were screened and based on inclusion and exclusion criteria (Supplementary Table 1; registered in ClinicalTrials.gov. NCT01758471), 106 patients were enrolled and 1:1 randomised into the two treatment arms (Supplementary Methods). There was no difference between the two arms in relation to gender, age and BMI (Table 1). Ninety-four of the enrolled patients completed the study and were included in the analyses, while 5 in the Acarbose group and 7 in the Glipizide group were not included in the analysis (flow chart shown in Supplementary Fig. 1). The goal of the treatment was to achieve a generally recommended targeted level of HbA1c below 7.0% in both arms within 3 months, indicative of improved glycaemic control. Faecal and plasma samples were collected at baseline and after 3 months of treatment. There were no significant differences between anthropomorphic, metabolic, biochemical parameters and HbA1c levels in the two groups at baseline (Wilcoxon rank-sum test, \( P > 0.05 \), Table 1).

**Fig. 1** Major clinical outcomes in patients after 3 months of treatment with Acarbose or Glipizide. **a** Effect on glycated haemoglobin A1c (HbA1c), in the Acarbose (brown) and Glipizide (white) arms, Wilcoxon rank-sum test. **b** Effects on fasting blood glucose concentration (FBG), postprandial blood glucose concentration (PBG) in the Acarbose (brown) and Glipizide (white) treatment arms; paired Wilcoxon rank-sum test, \( *P < 0.01 \). **c** Effects on body weight (BW) and body mass index (BMI) in the Acarbose (brown) and Glipizide (white) treatment arms. **d** Blood glucose excursion curve and **e** plasma insulin release curve during the meal tests in the two treatment arms, paired Wilcoxon rank-sum test, \( *P < 0.01 \), + \( P < 0.05 \), pre-treatment vs. post-treatment with Acarbose. **f** Effects on HOMA-IR, **g** Total cholesterol (TC) and triglycerides (TG) in the two treatment arms; paired Wilcoxon rank-sum test, \( *P < 0.01 \). \( n = 51 \) in Acarbose pre and Acarbose post-treatment, \( n = 43 \) in Glipizide pre and Glipizide post-treatment.
At the end of the 3-month treatment, the reductions in HbA1c levels, and fasting blood glucose (FBG) and postprandial blood glucose (PBG) levels were significant in both groups (paired Wilcoxon rank-sum test, \( P < 0.01 \) between baseline and treatment, Table 1), and both arms reached the targeted level of glycaemic control that did not differ significantly (Wilcoxon rank-sum test, \( P < 0.01 \) between baseline and treatment, Table 1).
rank-sum test, \( P > 0.05 \) between groups, Fig. 1a, b). However, the reductions in body weight (BW) and BMI were more pronounced in the Acarbose arm than in the Glipizide arm after 3 months of treatment (Fig. 1c). The area under the curve (AUC) value of insulin release was significantly reduced after Acarbose treatment, but increased as expected after Glipizide treatment during a carbohydrate meal test containing 100 g flour as described previously\(^{24}\), (1029.9 ± 575.2 pmol/L/min vs. 637.1 ± 342.6 pmol/L/min, Acarbose pre vs. post-treatment, \( P = 2.41 \times 10^{-06} \); 940.2 ± 431.7 pmol/L/min vs. 1139.6 ± 608.9 pmol/L/min, Glipizide pre vs. post-treatment, \( P = 0.019 \); paired Wilcoxon rank-sum test; Fig. 1d, e). In addition, patients receiving Acarbose but not
Glipizide showed a significant improvement in clinical parameters that are major risk factors for metabolic comorbidities and cardiovascular complications of T2D, such as the homeostasis model assessment of insulin resistance (HOMA-IR), total cholesterol (TC), triglyceride (TG) and fatty liver index (FLI)\(^{25}\). Of note, neither Acarbose nor Glipizide treatment increased, but rather decreased plasma FGF19 levels, a key factor produced in the intestine and shown to be of importance for metabolic health\(^{26,27}\), indicating that improvement in HbA1c and FBG and PBG levels was not dependent on FGF19, (Table 1; Fig. 1). all clinical parameters are given in Supplementary Table 2). Considering the known Acarbose-induced reduction of carbohydrate absorption in the small intestine, we next investigated to what extent Acarbose-induced changes in the gut microbiota might contribute to the observed additional metabolic benefits besides the hypoglycaemic effect.

Changes in plasma BAs correlate with therapeutic benefits. Alterations in the composition of the BA pool in humans can reflect intraluminal changes in the gut modulating gut-derived signals that regulate host metabolism and alteration in plasma BAs have been linked with metabolic disorders\(^{12}\). Thus, the level of tauro-conjugated BAs (TaurineBA, the sum of all tauro-conjugated BAs) is elevated in T2D\(^{26}\) and the ratio of 12-\(\alpha\) OH to non-12\(\alpha\) OH BAs (12-\(\alpha\) OH/non-12\(\alpha\) OH BA ratio) in the total BA pool has been linked to insulin resistance\(^{14}\). In our study, we assayed 15 BA species using high-performance LC-MS/MS on fasting plasma samples. At baseline, no differences in plasma BA levels were observed between the treatment arms (Fig. 2a). After treatment, plasma BA composition was substantially altered solely in the Acarbose arm with the level of total BAs remaining unchanged (Fig. 2b). Acarbose treatment decreased the levels of plasma secondary BAs (SBAs), mainly conjugated deoxycholic acids (DCAs). Due to the increased levels of cholic acid (CA) and chenodeoxycholic acid (CDCA), we observed an increased overall level of unconjugated primary BAs (PBAs). Further, the ratios of PBAs to SBAs (PBA/SBA ratio) and unconjugated to conjugated BAs (UnconBA/ConBA ratio) increased, whereas the levels of TaurineBA and the 12-\(\alpha\) OH/non-12\(\alpha\) OH BA ratio decreased after Acarbose treatment (Supplementary Table 3, paired Wilcoxon rank-sum test, \(P < 0.05\)).

A multivariate correlation analysis based on the generalised estimated equation (GEE) revealed that the Acarbose-induced improvements of glycaemic control and other metabolic parameters were correlated with the changes in plasma BA composition (Fig. 2c; Supplementary Table 4). The significant increases in the UnconBA/ConBA ratio and PBA/SBA ratio correlated with improvements in HbA1c, BW, FLI, blood pressure and lipid profile (Fig. 2c, Supplementary Table 4). Via deconjugation and the sequential dehydroxylation of PBAs to produce SBAs, the gut microbiome is crucial for regulating BA diversity\(^{27}\). The increased UnconBA/ConBA and PBA/SBA ratios after Acarbose treatment indicated that Acarbose treatment might alter two key steps of bacterial BA biotransformation.

Acarbose modulates the composition of the gut microbiota. We next performed whole-metagenome sequencing on the 188-paired faecal samples from the patients and generated 1.42 Tb of high-quality sequencing data with an average of 7.7 Gb per sample to investigate the differential responses of the gut microbiome to the two types of antidiabetic treatment. Genes were identified by aligning the reads to the 9.9 M integrated reference catalogue of genes in the human gut microbiome\(^{28}\). On average, 80.5\% of the reads in each sample were mapped (Supplementary Table 5). Metagenomic analyses demonstrated that Acarbose treatment significantly altered the relative abundances of 141,382 microbial genes (paired Wilcoxon rank-sum test, \(q < 0.01\)), whereas no significant changes in relative gene abundances were observed following Glipizide treatment (Supplementary Table 5). Rarefaction analyses revealed that the number of genes in the microbiomes of patients in the Acarbose arm surprisingly was significantly decreased, whereas no changes were observed in the Glipizide arm (Fig. 3a, b). In line with this observation, both gene count and Shannon index decreased after Acarbose treatment, but not after Glipizide treatment (Fig. 3c, d). Analysis of species-level molecular operational taxonomic unit (mOTU) profiles demonstrated that Acarbose led to significant changes in the relative abundances of 69 mOTUs (paired Wilcoxon rank-sum test, \(q < 0.01\); Fig. 3e; Supplementary Table 6); Glipizide treatment did not affect the relative abundances of any mOTUs at this significance level. At baseline, there were no significant differences in relation to gene rarefaction, gene richness and gut microbiome alpha diversity or taxonomic richness between the two arms (Supplementary Fig. 2, Fig. 3c, d). Of note, despite of the comparable hypoglycaemic effect of Glipizide and Acarbose treatment, the gut microbiome alteration after Glipizide treatment was small, suggesting that changes in blood glucose levels were not a primary driver of the changes in the distal gut microbiota. Unlike Glipizide that regulates the ATP-sensitive potassium (K\(_{ATP}\)) channel activity of pancreatic \(\beta\) cells, Acarbose impedes the hydrolysis and absorption of carbohydrates in the small intestine, which in turn changes the abundances of substrates for fermentation by the microbiota in the distal intestine, thereby allowing saccharolytic Lactobacillus and Bifidobacterium species to thrive and depleting the original distal gut-residing, putrefactive species of Bacteroides, Allistipes and Clostridium (Fig. 3c, paired Wilcoxon rank-sum test, \(q < 0.01\)).

Plasma BA changes, metabolic benefits and gut microbiota. A mutual interaction between host BAs and the gut microbiome modulates the microbial biotransformation of BAs\(^{29}\). In the untreated T2D patients at baseline, permutation multivariate analysis of variance (PERMANOVA) analysis revealed that plasma levels of the SBAs, ursodeoxycholic acid (UDCA), glycochols deoxycholic acid (GUDCA), lithocholic acid (LCA) and

Fig. 3 Acarbose elicits stronger impact on the gut microbiota than Glipizide. Effects of Acarbose \(a\) and Glipizide \(b\) treatments on gene rarefaction, \(n = 51\) in Acarbose pre and Acarbose post-treatment, \(n = 43\) in Glipizide pre-treatment and Glipizide post-treatment. All bar plots are shown as mean ± S.D. The number of genes in each group was calculated after 100 random samplings with replacement. The effects of treatment in both arms on gene richness \(c\) and Shannon index \(d\) of the gut microbiome, \(n = 51\) in Acarbose pre and Acarbose post-treatment, \(n = 43\) in Glipizide pre and Glipizide post-treatment. e mOTUs significantly changed in abundance by Acarbose treatment (left panel), Benjamini-Hochberg q-value < 0.01, presented in box-plots to illustrate the relative abundances of the different groups. The mOTUs are listed in the order of their relative abundances pre-treatment, mOTUs in red represent mOTUs that decreased in abundance are after Acarbose treatment, whereas mOTUs that increased in abundance are given in green. The phylum colour code is indicated to the left of the mOTU annotation. The same mOTUs did not change after Glipizide treatment (right panel of e). All plotted boxes are interquartile ranges. Dark lines in the boxes indicate medians, the lowest and highest values within 1.5 times IQR from the first and third quartiles. Outliers are shown as circles beyond the whiskers. n = 51 in Acarbose, n = 43 in Glipizide, *Bifidobacterium catenulatum–Bpc: Bifidobacterium catenulatum–Bifidobacterium pseudocatenulatum complex
DCA correlated with changes in the composition of the gut microbiota (Bray–Curtis distance, \( q < 0.01 \); Supplementary Table 7). Interestingly, 58 out of the 69 mOTUs that exhibited significant changes in relative abundance in response to Acarbose treatment also correlated with Acarbose-induced alterations in plasma BA composition (GEE adjusted for age, sex and BMI, \( q < 0.05 \); Supplementary Data 1), pointing to a tight link between Acarbose-dependent alterations of the gut microbiota and plasma BA composition. Many of the Acarbose-induced species have been classified and used as probiotics, and the increase in the relative abundance correlated with improvements in metabolic parameters (GEE adjusted for age, sex and BMI, \( q < 0.05 \); Supplementary Fig. 3). Thus, Acarbose-induced increases in \textit{Lactobacillus gasseri} and \textit{Bifidobacterium longum} correlated inversely with changes in BW and HbA1c. These correlations are consistent with those observed in mice treated with VSL3# (a probiotic supplement containing strains of \textit{Lactobacillus}, \textit{Bifidobacterium} and \textit{Streptococcus})\(^{30}\) and
with the effect of microbial overexpression of the gene encoding bile salt hydrolase (Bsh) which also increased the UnconBA/ConBA ratio in mice. The reduced plasma DCA levels and reduced BW gain after Acarbose treatment, correlated with the reductions of Acarbose-depleted species, such as Bacteroides plebeius, Bacteroides dorei/vulgatus and Clostridium bolteae. These species harbour a multi-gene BA-inducible (bai) operon encoding genes involved in 7α/β dehydroxylation of BAs, reported not to be present in probiotic bacteria.

Acarbose treatment alters gut bile acid composition. To explore the possible impact of Acarbose on gut bacterial BA metabolism, we performed functional annotations of genes using a manually built reference library which includes 1011 annotated amino acid sequences mapped to 16,102 genes implicated in bacterial BA metabolism (Supplementary Table 8). The relative abundances of genes encoding enzymes involved in bacterial BA modification, including BA deconjugation, BA transport, hydroxysteroid dehydrogenation and 7α/β dehydroxylation were thus calculated and compared between pre-treatment and post-treatment samples (Supplementary Table 8). The relative abundances of baiE (encoding BA 7α-dehydroxylase, the rate-limiting enzyme for 7α-dehydroxylation) and baiI (encoding BA 7β-dehydroxylase) were significantly decreased after Acarbose treatment, while the baiG (encoding BA transporter) and genes encoding 7β-Hsdh (7β-hsdh) showed significant enrichment after Acarbose treatment (paired Wilcoxon rank-sum test, \( p < 0.05 \); Fig. 4a; Supplementary Table 9). None of these genes changed significantly in relative abundance after Glipizide treatment (paired Wilcoxon rank-sum test, \( p > 0.05 \); Fig. 4a; Supplementary Table 9).

The taxa distributions of genes involved in BA metabolism (Supplementary Data 2) in baseline samples revealed that B. plebeius, B. vulgaris/dorei and B. dorei largely accounted for the abundances of bsh, baiG and baiI. This suggested that these Bacteroides species were mainly responsible for both BA deconjugation and subsequent dehydroxylation in the distal gut microbiota of treatment-naive T2D patients. After treatment, the relative abundances of these genes were reduced due to the loss of their dominant contributor species, or the dominant contributors of some genes were replaced by other species. For example, the dominant contributors of the genes encoding Bsh changed from B. plebeius and B. vulgaris/dorei to B. longum, and Lactobacillus amylovorus (Fig. 4b). The Bifidobacterium and Lactobacillus genera have been reported to possess high Bsh activity, but are lacking the bai genes.

We investigated if the changes in the bacterial potential for BA metabolism induced by Acarbose treatment were reflected in the BA composition in the faecal samples. The total level of faecal BAs was significantly decreased after Acarbose treatment (Supplementary Fig. 4a, b, Supplementary Table 10). Actually, the faecal levels of the primary BAs, CA and CDCA, increased following Acarbose treatment, but this was more than counteracted by the large decrease in the levels of the secondary BAs, DCA and LCA (Supplementary Fig. 4a). Overall, these changes resulted in an increased faecal PBA/SBA ratio in response to Acarbose treatment (Supplementary Fig. 4d). The faecal UnconBA/ConBA ratio was unchanged (Supplementary Fig. 4c). These changes mirrored the changed relative abundance of bai genes with an even more relative abundance of bsh genes following Acarbose treatment (illustrated in Fig. 4c), but do not explain the significant increase in the plasma UnconBA/ConBA ratio after Acarbose treatment.

In addition to altering BA metabolism, bacterial functional pathway analysis showed that Acarbose treatment also increased the potential for glutamine synthesis, decreased the potential for glycosaminoglycan degradation, and decreased the potential for F6S- and methane production (Supplementary Data 3), all associated with host-gut barrier integrity and T2D risks. Finally, both antidiabetic treatments reduced the abundances of genes involved in type III secretion and LPS biosynthesis that are linked to insulin resistance, suggesting the existence of certain common routes in the response of the gut microbiome to antidiabetic treatments despite the use of different medical agents.

Microbiota composition predicts the response to Acarbose. Studies have suggested a stratification of individuals by clustering algorithms based on the genus composition of the intestinal microbiota, but the concept of the existence of discrete enterotypes has also been questioned, suggesting a continuous distribution of enterotypes in an individual. In our study, the baseline microbiomes of patients could be clearly separated into two enterotype-like clusters, one driven by Bacteroides (Cluster B) and the other driven by Prevotella (Cluster P) shown by PCA analysis (Supplementary Fig. 5a), network analysis (Supplementary Fig. 5b) and abundance box plot (Supplementary Fig. 5c). In agreement with previous reports, anthropomorphic, metabolic and biochemical parameters did not differ between patients from the two clusters (Wilcoxon rank-sum test, \( p > 0.05 \), Supplementary Table 11). However, already at baseline patients in Cluster B had lower levels of LCA and DCA, and higher levels of UDCA in the BA pool both in plasma and faeces (Wilcoxon rank-sum test, \( p < 0.05 \); Fig. 5a; Supplementary Tables 12, 13). Patients in Cluster B also exhibited a higher plasma PBA/SBA ratio and lower 12α OH/non-12α OH BA ratio compared to...
patients in Cluster P (Wilcoxon rank-sum test, \( P < 0.05 \), Fig. 5a; Supplementary Table 12). Further, patients in Cluster B exhibited significantly decreased relative abundance of baiG, but increased relative abundances of bsh, and \( 7\beta\)-hshdh, whereas baiE and baiI exhibited similar relative abundances in both clusters (Wilcoxon rank-sum test, \( P < 0.05 \), Supplementary Table 14). Interestingly, the clinical effects of Acarbose were more pronounced in patients belonging to Cluster B than in patients belonging to Cluster P. Despite a similar improvement in Hba1c levels by Acarbose treatment, patients in Cluster B exhibited significantly greater improvements in G0 (FBG), insulin, C peptide levels and, therefore, HOMA-IR over baseline levels than patients in Cluster P (Fig. 5b; Supplementary Fig. 6a; Wilcoxon rank-sum test, \( P < 0.05 \), see also Supplementary Table 15 for all results). We observed the same tendency in the Gilipizide arm. The compositions of the gut microbiome of patients in Cluster B changed significantly with depletion of the dominant Bacteroides genus and the increase of the Bifidobacterium genus after treatment, whereas fewer changes were observed in the gut microbiomes of patients belonging to Cluster P (Supplementary Fig. 6b; Wilcoxon rank-sum test, \( P < 0.01 \)). Further, Acarbose treatment led to a decreased abundance of baiE and an increased abundance of \( 7\beta\)-hshdh and baiG, exclusively in patients in Cluster B (Supplementary Fig. 6c). Together, these results suggest that some of the therapeutic effects of Acarbose-induced modulation of the gut microbiota are related to bacterial BA metabolism and, therefore, BA signalling.

**Discussion**

This study compared the effects of two antidiabetic drugs on the gut microbiota, plasma BAs and their relations with clinical outcomes in a clinical trial-based cohort. A key finding of this study is that the baseline composition of the gut microbiota may be used for stratification of patients prior to initiation of treatment.

The significant reductions in BW with targeted glycaemic control after Acarbose treatment is in line with earlier studies. Further, we demonstrate that patients receiving Acarbose, but not Glipizide showed a significant improvement in the HOMA-IR, lipid profile and FLI. The results of plasma BA profiling and the multiple correlations between changes of plasma BAs and clinical parameters, including BW, HOMA-IR, lipid profile and FLI, indicate that the modulation of BA signalling may contribute to the unique metabolic effects of Acarbose. The increased levels of plasma CDCA and an increased UnconBA/ConBA ratio induced by Acarbose may enhance in vivo FXR activity and change the faecal BA composition, resulting in decreased intestinal lipid absorption and reduced hyperglycaemia. Interestingly, plasma UnconBA/ConBA and PBA/SBA ratios were also shown to increase after biliopancreatic diversion surgery, which in a 2-year follow-up study was reported to result in superior improvements in hyperglycaemia and dyslipidaemia compared to the Roux-en-Y bypass and conventional medical therapy. The notion that similar changes in BA composition and correlations between metabolic traits and plasma BAs after both Acarbose treatment and gut reconstruction surgeries, despite differences in populations, sample size and follow-up time, points to the importance of BA signalling in metabolic control in T2D treatments.

Acarbose treatment led to increased abundances of species possessing high Bsh activity, mainly B. longum, L. gasseri and reduced abundance of the SBA producers, B. plebeius, B. vulgaris/dorei and C. bolteae. Further functional analysis showed decreased abundances of genes encoding the rate limited enzyme for \( 7\alpha/\beta \) dehydroxylation and a switch in the main contributors of BA deconjugation enzymes from Bacteroides spp. to Lactobacillus and Bifidobacterium spp., which barely contain bai genes. Thus, the metagenomics analyses indicated lower capacity for BA \( 7\alpha/\beta \) dehydroxylation after Acarbose treatment, which is in keeping with the observed increased plasma and faecal PBA/SBA ratios.

Interestingly, the increased ratio of UnconBA/ConBA was observed in plasma, but not in faecal samples, and the abundances of bacterial bsh genes did not change either. This would argue against an increased potential of bacterial deconjugation in response to Acarbose treatment, even in patients harbouring higher abundancies of species such as B. longum and L. gasseri which have been reported to possess high Bsh activity. However, deconjugation occurs in the upper part of intestine and most of unconjugated PBA are reabsorbed in the ileum, and thus, to
what extent the UnconBA/ConBA ratio in the faecal sample represents a valid proxy for in vivo bacterial deconjugation capacity needs to be further investigated. It is possible that the significantly reduced level of FGF19, which conveys the main inhibitory intestinal BA signal for hepatic BA neo-synthesis and an altered intestinal BA reabsorption after Acarbose treatment may contribute to the discrepancy between the UnconBA/ConBA ratios in plasma and faecal samples. However, taken together our results clearly point to the importance of Acarbose-induced changes in the composition of the gut microbiome and the observed alterations in BA profiles.

With the increased attention on the metabolic significance of BA signalling, the discovery of an Acarbose-gut microbiota-BA axis may aid the identification of novel modalities for therapeutics intervention targeting the gut microbiome or plasma BAs. The implication of gut microbiota-plasma BA axis underlying therapeutic effects of Acarbose is further supported by the finding of more pronounced changes in plasma BA composition and clinical benefits of Acarbose treatment in patients where the baseline microbiomes belonged to an enterotype-like cluster driven by Bacteroides (Cluster B) vs. those belonging to an enterotype-like cluster driven by Prevotella (Cluster P).

In conclusion, our results suggest that the differential therapeutic responses are related to distinct abilities of the microbial communities in the two microbiome clusters to metabolise BAs, and, more importantly, our findings demonstrate that stratification of patients according to baseline gut microbiota composition may provide a tool for selecting medication strategy and predicting antidiabetic metabolic benefits.

**Methods**

**Trial design.** This study was a randomised, open-label, two-arm, multicentre clinical trial. Five centres participated in this study: Ruijin Hospital, Renji Hospital, Xinhua Hospital, all affiliated to Shanghai Jiaotong University Medical School, Shanghai General Hospital affiliated to Shanghai Jiaotong University and the Central Hospital of Minhang District affiliated to Fudan University Medical School. The study was approved by the Institutional Review Board of each hospital and is registered at ClinicalTrials.gov (NCT01758471). Written informed consent was obtained from each patient. The study was conducted in accordance with the principles of the Declaration of Helsinki. Randomisation and treatment. After administration of a glucose tolerance test and evaluation of other baseline characteristics, eligible patients were diagnosed according to the 1999 World Health Organization criteria with fasting plasma glucose ≥7 mmol/L and/or an oral glucose tolerance test (OGTT) 2 h ≥11.1 mmol/L and randomly assigned to receive either Acarbose or Glipizide treatment, (detailed screening and recruitment procedures are provided in the Supplementary Methods, Screening, recruitment, dietary information and follow-up). The randomisation codes were generated with SAS (version 9.2; SAS Institute, Cary, NC) by a biostatistician who did not participate in the enrolment of patients. A formal power analysis was not performed to calculate sample size. The sample size for this interventional study was selected based on previous studies of changes in the composition of the gut microbiota in T2D and other diseases that compared the effects of different therapeutic strategies on intestinal microbiota, considering potential withdrawal and loss to follow-up.

Patients were instructed to visit every month for the measurement of fasting and postprandial glucose levels. The drug dosage was modified according to the glycaemic control at each visit (targeted FBG ≤7.0 mmol/L and PBG ≤10.0 mmol/L). After 3 months of treatment, all patients were again confidential in the hospital as for the run-in period, served the same meals for lunch and dinner as during the first visit, fasted overnight and given an oral glucose load the next morning. Blood samples, faeces and urine were collected as described above (more details are provided in the Supplementary Methods, Screening, recruitment, dietary information and follow-up).

**Sample preparation.** One day before the first visit, the enrolled patients were confined in the hospital and served the same meals for lunch and dinner. Faeces and urine were collected in dispensible sterile containers. Samples were kept on dry ice before being stored at −80°C. Patients were fasted overnight. At 0800 hours, the patients ingested a carbohydrate meal containing 100 g of flour as an oral glucose load and blood samples were taken before and 60 min, 120 min and 180 min after the meal test. The blood samples were immediately supplemented with a dipetylïpid peptide-4 inhibitor (for GLP-1 measurement; Millipore, Billerica, MA, USA), the serine protease inhibitor Pefabloc SC (AEBSF for active ghrelin measurement; Roche, Basel, Switzerland) and a protease inhibitor cocktail (Millipore, Billerica, MA, USA). Serum and plasma samples were prepared and kept on dry ice before storage at −80°C.

**Laboratory assays.** Plasma levels of cytokines and hormones were measured using standard kits (Millipore, Billerica, MA, USA) on a Luminox FlexM3D system with xMAP LumineX technology. HbA1c was measured by high-performance liquid chromatography using the VARIANT II HbA1C Testing System (Bio-Rad Laboratories, Hercules, CA, USA). Plasma BAs were assayed by LC-MS/MS with multiple reaction monitoring, using a 1290 Infinity LC system (Agilent, Santa Clara, CA, USA) coupled with 6460 A Triple Quadrupole mass spectrometer (AB Sciex, Framingham, MA) was used in analysis of BAs in faecal samples. Chromatographic separation was performed on a 100 mm × 2.1 mm ACQUITY UPLC C8 column for plasma samples and UPLC BEH C18 column for faecal samples with 1.7 μm particle size (Waters, Milford, MA, USA). Sample preparations for BA assay were performed as described previously.

Glucose and biochemical parameters for assaying hepatic function, renal function, blood electrolytes and lipid profiles were determined using the AU8800 Clinical Chemistry System (Beckman Coulter, Brea, CA, USA).

**Metagenomic sequencing and annotation.** DNA was extracted from stool samples as described previously. We constructed one DNA paired-end (PE) library with an insert size of 350 base pairs (bp) for each sample following the manufacturer’s instructions (illumina, San Diego, California, USA). All samples were sequenced using the 100-bp PE strategy on Illumina HiSeq 2500. The sequencing data are available at the European Nucleotide Archive with code PRJEB12124. Adaptor contamination and low-quality reads were discarded from the raw reads, and the remaining reads were filtered to eliminate human host DNA based on the human genome reference (hg18). The gene profiles were generated by aligning high-quality sequencing reads to the reference genome catalogue as previously described. Similarly, the relative abundance profiles of genera, species and Kyoto Encyclopedia of Genes and Genomes (KEGG) orthologous groups (KO)s were determined from the gene abundances of mOTUs were obtained using mOTU profiling software.

**Analysis of richness and biodiversity.** Rarefaction and α-diversity analysis (within-sample diversity) were performed as described by Li et al. The gene counts in each faecal sample were determined as previously reported. Rarefaction analysis was performed to assess gene richness in the T2D patients before and after the patients had been treated with drugs for 3 months. For the rarefaction analysis, we performed random sampling 100 times in the cohort with replacement and estimated the total number of genes that could be identified from these samples using the Chao2 richness estimator. To minimise erroneous identification, only the genes with ≥2 pair of mapped reads were considered to be present in a sample.

**Correlations between microbial genes and plasma BA species.** The interactions between gene abundance profiles and each of the 15 plasma BA species were assessed by PERMANOVA with the Bray–Curtis distance. The number of permutations was 9999 (performed using the vegan package in R 3.3.1).

**Multivariate regression analysis.** A GEE analysis (corrected for age, sex and BMI) was performed to explore Acarbose-induced longitudinal associations between changes in (1) BA species and clinical parameters, (2) BA species and the mOTUs significantly altered in relative abundance by Acarbose and (3) the mOTUs significantly altered in relative abundance by Acarbose and clinical parameters. The P value of each regression coefficient was calculated, and an adjusted P value of <0.05 was considered significant (performed using the gee package in R 3.3.1). All regression analyses between BW and other traits were conducted after adjustment for age and sex, but not BMI.

**KEGG enrichment analysis.** Differentially enriched KO modules were identified according to their reporter scores from the Z-scores of individual KOs as described previously. An absolute value of reporter score of 1.95 or higher was used as the detection threshold for significance.

**Clustering of microbial community types.** Samples were clustered based on the genus profiles. Two enterotype-like clusters were identified in our samples using the method described previously. In this study, samples were clustered using Jensen–Shannon distance and presented by a PCA (Principal Component Analysis) graph implemented in the ‘ade4’ package in R.

**Identification of microbial genes involved in BA biotransformation.** We retrieved 11 enzymes involved in microbial BA metabolism from UniProt (UniProt Protein Resource) protein database. After removing redundant sequences with greater than 90% identity, a total of 1011 amino acid sequences were obtained.
16,102 potential-hits against KEGG using BlastKOALA (KEGG Orthology And Supplementary Data). 4

differences in clinical parameters, BAs, genes and mOTUs pre-treatment and post-treatment. If the species contributed more than 0.5% of the total pool, this species was considered as a dominant contributor.

**Statistical analyses** Paired Wilcoxon rank-sum tests were conducted to detect differences in clinical parameters, BAs, genes and mOTUs pre-treatment and post-treatment. P values were adjusted by the Benjamini–Hochberg correction. A P value or an adjusted P value of less than 0.05 was considered significant.

**Data availability** Metagenomic sequencing data for all samples have been deposited in the European Bioinformatics Institute (EBI) database under accession code PRJEB12124. All other data are available upon request.

Received: 29 March 2017 Accepted: 9 October 2017 Published online: 27 November 2017

**References**

46. Song, K. H., Li, T., Owley, E., Strom, S. & Chiang, J. Y. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit...


Acknowledgements

We thank Mr. Yixin Wu, Mr. Wenzhong Zhou and Ms. Qun Zhang of the Central Laboratory, Shanghai Institute of Endocrine and Metabolic Diseases, for help with analysing HbA1c levels. We also thank Dr. H. Bjorn Nielsen and Dr. Susanne Brix of the Technical University of Denmark for their valuable inputs and discussions. We also thank Shanghai ProfLeader Biotech Co., Ltd. for the assistance with the analysis of faecal material in this article are included in the article indicated otherwise in a credit line to the material. If material is not included in the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Author contributions


Additional information

Supplementary Information accompanies this paper at doi:10.1038/s41467-017-01682-2.

Competing interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2017